265 related articles for article (PubMed ID: 10845730)
21. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
23. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.
Cereghino JJ; Biton V; Abou-Khalil B; Dreifuss F; Gauer LJ; Leppik I
Neurology; 2000 Jul; 55(2):236-42. PubMed ID: 10908898
[TBL] [Abstract][Full Text] [Related]
24. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.
Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D
Epilepsy Behav; 2008 Feb; 12(2):305-10. PubMed ID: 18024209
[TBL] [Abstract][Full Text] [Related]
25. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials.
Uthman BM; Almas M; Emir B; Giordano S; Leon T
Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392
[TBL] [Abstract][Full Text] [Related]
26. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial.
Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J;
Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.
Beydoun A; Uthman BM; Kugler AR; Greiner MJ; Knapp LE; Garofalo EA;
Neurology; 2005 Feb; 64(3):475-80. PubMed ID: 15699378
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Li S; Cao J; Xiao N; Cai F
J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
[TBL] [Abstract][Full Text] [Related]
29. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of levetiracetam as adjunctive therapy in Japanese patients with uncontrolled partial-onset seizures.
Inoue Y; Yagi K; Ikeda A; Sasagawa M; Ishida S; Suzuki A; Yoshida K;
Psychiatry Clin Neurosci; 2015 Oct; 69(10):640-8. PubMed ID: 25854635
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients.
Heo K; Lee BI; Yi SD; Huh K; Kim JM; Lee SA; Shin DJ; Song HK; Lee SK; Kim JY; Lu S; Dubois C; Tonner F
Seizure; 2007 Jul; 16(5):402-9. PubMed ID: 17369059
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
[TBL] [Abstract][Full Text] [Related]
33. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
34. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre.
Kang BS; Moon HJ; Kim YS; Lee ST; Jung KH; Chu K; Lee SK
Epileptic Disord; 2013 Sep; 15(3):302-10. PubMed ID: 23981665
[TBL] [Abstract][Full Text] [Related]
35. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.
Berkovic SF; Knowlton RC; Leroy RF; Schiemann J; Falter U;
Neurology; 2007 Oct; 69(18):1751-60. PubMed ID: 17625106
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
37. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.
Noachtar S; Andermann E; Meyvisch P; Andermann F; Gough WB; Schiemann-Delgado J;
Neurology; 2008 Feb; 70(8):607-16. PubMed ID: 18285535
[TBL] [Abstract][Full Text] [Related]
38. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
39. Levetiracetam in pediatrics.
Vigevano F
J Child Neurol; 2005 Feb; 20(2):87-93. PubMed ID: 15794171
[TBL] [Abstract][Full Text] [Related]
40. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Kinirons P; McCarthy M; Doherty CP; Delanty N
Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
